In a study of non-small-cell lung cancer (NSCLC), CD38+CD8+TRM was also observed within the TME (29) and was shown to be crucial for anti-tumor immunity in NSCLC (28). This evidence concerns the gene CD38 and non-small cell lung carcinoma.